Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

Company Overview - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to address the underlying causes of diseases by modulating the expression of specific disease-causing genes [3] Product Development - Design Therapeutics is advancing several programs, including DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy [3] - The company is also working on therapies for myotonic dystrophy type-1 and Huntington's disease, with ongoing discovery efforts for multiple genomic medicines [3] Upcoming Events - Management will participate in a fireside chat at Leerink's Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET in Miami [1] - A live webcast of the event will be available on the company's website and archived for at least 30 days [2]